Publikation

Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma - a phase II trial

Wissenschaftlicher Artikel/Review - 16.12.2016

Mey Ulrich J M, Ruefer Axel, Ziske Carsten, Knauf Wolfgang, Cathomas Richard, von Moos Roger, Hitz Felicitas, Sauter Rafael, Hiendlmeyer Elke, Cantoni Nathan, Bargetzi Mario, Fischer Natalie, Doerfel Steffen, Brugger Wolfram, Schwarb Heike, Pederiva Stefanie, Schwarzer Andreas, Dechow Tobias, Jehner Paul, Rauh Jacqueline, Taverna Christian J, Schmid Mathias, Schmidt-Hieber Martin, Driessen Christoph